研究成果
年分
作者
期刊
研究名稱
2022
Chang HY*, Fang HL, Huang CY, Chiang CY, Chuang SY, Hsu CC, Cheng HM, Chen TW, Yao WC, Pan WH.
2022; 19(3): 1319. (IF:4.614)
Developing and Validating Risk Scores for Predicting Major Cardiovascular Events Using Population Surveys Linked with Electronic Health Insurance Records. Int. J. Environ. Res. Public Health.
2022
Chang LH, Chu CH, Huang CC, Lin LY*.
Front. Endocrinol. 2022; 13:846018. (IF: 6.055)
Fibroblast Growth Factor 21 Levels Exhibit the Association With Renal Outcomes in Subjects With Type 2 Diabetes Mellitus.
2022
Chang PY, Wang WT, Wu WL, Chang HC, Chen CH, Tsai YW*, Chiou SH, Lip GYH, Cheng HM*, Chiang CE.
Thromb. Haemost. 2022; 122(06): 939-950. (IF: 6.830)
Oral Anticoagulation Timing in Patients with Acute Ischemic Stroke and Atrial Fibrillation.
2022
Chang TT*, Chen C, Chen JW.
Cardiovasc. Diabetol. 2022; 21(1): 185. (IF:8.949)
CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease.
2022
Chang TT*, Chen C, Lin LY, Chen JW*.
Biomedicines. 2022; 10(8): 1963. (IF: 4.757)
CCL4 Deletion Accelerates Wound Healing by Improving Endothelial Cell Functions in Diabetes Mellitus.
2022
Chang TT*, Chen JW.
Antioxidants. 2022; 11(11):2224. (IF: 7.675)
Potential Impacts of Hydralazine as a Novel Antioxidant on Cardiovascular and Renal Disease-Beyond Vasodilation and Blood Pressure Lowering.
2022
Chang TT*, Chiang CH, Chen C, Lin SC, Lee HJ, Chen JW*.
Biomed. Pharmacother. 2022; 151 :113139. (IF: 7.419)
Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy.
2022
Chang TY, Chen KW, Liu CM, Chang SL*, Lin YJ, Lo LW, Hu YF, Chung FP, Lin CY, Kuo L, Chen SA.
J. Pers. Med. 2022; 12(5):764. (IF: 3.508)
A High-Precision Deep Learning Algorithm to Localize Idiopathic Ventricular Arrhythmias.
2022
Chang TY, Lu CT, Huang HL, Chou RH, Chang CC, Liu CT, Huang PH*, Lin SJ.
Front. Cardiovasc. Med. 2022; 9:882181. (IF: 5.848)
Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study.
2022
Chao TF*, Chan YH, Chiang CE, Tuan TC, Liao JN, Chen TJ, Lip GYH*, Chen SA.
Eur. Heart J.-Qual. Care Clin. Outcomes. 2022; 8(7): 730-738. (IF: 7.064)
Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk.